Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting NEW YORK--(BUSINESS WIRE)

Announces Two Oral Presentations and One Poster at the 2016 ASH Annual

NEW YORK--(BUSINESS WIRE)--November 7, 2016--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),

a biopharmaceutical company focused on developing immunotherapies based

on gene edited CAR T-cells (UCART), today announced that abstracts

regarding the Company's allogeneic, off-the-shelf, CAR T programs have

been accepted for presentation at the 58th American Society of

Hematology (ASH) Annual Meeting and Exposition. The meeting will be held

December 3-6, 2016 in San Diego.

765 Allogeneic Tcr / Deficient CAR T-Cells Targeting CD123 Prolong

Overall Survival of AML Patient-Derived Xenografts

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation

Oral and Poster Abstracts

Session: 616. Acute Myeloid

Leukemia: Novel Therapy, excluding Transplantation: Emerging

Immune-Based Therapies for AML

Monday, December 5, 2016: 11:00 AM

Diego Ballroom AB (Marriott Marquis San Diego Marina)

Monica L. Guzman, PhD1, Mayumi Sugita, MD1*,

Hongliang Zong, MD, PhD1*, Nathan Ewing-Crystal1*,

Vicenta Trujillo-Alonso1*, Nuria Mencia-Trinchant, PhD1*,

Linda Lam1*, Nicole M. Cruz, MD1, Roman Galetto,

PhD2*, Agn s Gouble, PhD2*, Duane C Hassane,

PhD1, Julianne Smith, PhD2 and Gail J. Roboz3

of Hematology and Medical Oncology, Department of Medicine, Weill

Cornell Medical College, New York, NY

3Weill Cornell Medical

College, New York, NY

381 Preclinical Evaluation of Allogeneic Anti-Bcma Chimeric Antigen

Receptor T Cells with Safety Switch Domains and Lymphodepletion

Resistance for the Treatment of Multiple Myeloma

Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy

Oral and Poster Abstracts

Session: 652. Myeloma:

Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel

Immune Approaches for Myeloma Therapy

Sunday, December 4, 2016:

Grand Hall B (Manchester Grand Hyatt San Diego)

Bijan Boldajipour, PhD1*, Roman Galetto, PhD2*,

Cesar Sommer, PhD1*, Thomas Pertel, PhD1*, Julien

Valton, PhD3*, Yoon Park, PhD1*, Annabelle

Gariboldi2*, Amy Chen1*, Tao Geng1*,

Hong H Dong1*, Gregory R Boucher1*, Thomas J Van

Blarcom, PhD1*, Javier Chaparro-Riggers, PhD1*,

Arvind Rajpal, PhD1*, Julianne Smith, PhD3, Tracy

Kuo, PhD1* and Barbra Sasu, PhD1

Inc., South San Francisco, CA

3Cellectis Inc., New York, NY

Poster presentation:

4039 Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the

Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation

Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel

Therapy, excluding Transplantation: Poster III

2016, 6:00 PM-8:00 PM

Hall GH (San Diego Convention Center)

Tianyu Cai, PhD1*, Roman Galetto, PhD2*,

Agn s Gouble, PhD2*, Julianne Smith, PhD2,

Antonio Cavazos, MS1*, Sergej Konoplev, MD, PhD3,

Andrew A. Lane, MD, PhD4, Monica L. Guzman, PhD5,

Hagop M. Kantarjian, MD1, Naveen Pemmaraju, MD1

and Marina Konopleva, MD, PhD1

of Leukemia, The University of Texas MD Anderson Cancer Center, Houston,

2Cellectis SA, Paris, France

of Hematopathology, The University of Texas MD Anderson Cancer Center,

4Dana-Farber Cancer Institute,

5Division of Hematology and

Medical Oncology, Department of Medicine, Weill Cornell Medical College,

Cellectis is a biopharmaceutical company focused on developing

immunotherapies based on gene edited CAR T-cells (UCART). The company's

mission is to develop a new generation of cancer therapies based on

engineered T-cells. Cellectis capitalizes on its 16 years of expertise

in genome engineering - based on its flagship TALEN products and

meganucleases and pioneering electroporation PulseAgile technology - to

create a new generation of immunotherapies. CAR technologies are

designed to target surface antigens expressed on cells. Using its

life-science-focused, pioneering genome-engineering technologies,

Cellectis' goal is to create innovative products in multiple fields and

with various target markets.

In June 2014, Cellectis and Pfizer began collaborating on a joint

clinical development program for CAR-T therapies, in the field of

oncology, directed at numerous targets selected by Pfizer.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE

Alternext market (ticker: ALCLS). To find out more about us, visit our

website: www.cellectis.com

Talking about gene editing? We do it. TALEN is a registered trademark

owned by the Cellectis Group.

This press release and the information contained herein do not

constitute an offer to sell or subscribe, or a solicitation of an offer

to buy or subscribe, for shares in Cellectis in any country. This press

release contains forward-looking statements that relate to the Company's

objectives based on the current expectations and assumptions of the

Company's management only and involve risk and uncertainties that could

cause the Company to fail to achieve the objectives expressed by the

forward-looking statements above.

Jennifer Moore, 917-580-1088